• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

SonoThera licenses GE HealthCare microbubbles for guided gene therapy delivery

February 28, 2023 By Sean Whooley

GE HealthCare Optison microbubbles SonoThera
The GE HealthCare Optison microbubbles. SonoThera entered a licensing agreement for this product, along with the Sonazoid microbubbles. [Image from GE HealthCare]
SonoThera announced that it received exclusive global commercial licensing rights from GE HealthCare (NYSE:GEHC) for two of its microbubble products.

South San Francisco-based SonoThera received the rights for the Optison and Sonazoid microbubble products. It uses them in the development of its novel, ultrasound-guided nonviral gene therapy platform.

According to SonoThera co-founder and CEO Kenneth Greenberg, the company aims to develop the next generation of non-viral genetic therapies. These therapies would feature capabilities for selective delivery to “multiple target organs in a safe and efficacious manner.”

“Our preclinical testing has demonstrated that the platform can address many of the key delivery challenges facing current gene therapy approaches,” Greenberg said.

SonoThera’s ultrasound-guided platform uses sonoporation. This microbubble-mediated biophysical process non-invasively delivers genetic payloads of diverse formats and sizes. It selectively targets a wide range of organs within the body. Unlike traditional gene therapies, it does not require viral vectors, SonoThera said.

The companies declined to disclose the terms of the licensing agreement. SonoThera currently has the technology under pre-clinical development as it prepares for Phase 1 clinical trials.

“SonoThera’s development of an ultrasound-guided, nonviral gene platform aligns with our dedication to providing innovative, precision care and therapies to patients in order to improve their healthcare outcomes,” said Sigrid Fossheim, global ultrasound product leader at GE HealthCare’s Pharmaceutical Diagnostics unit. “We believe what SonoThera is developing has the potential to improve patient care by overcoming the current challenges of existing gene therapies.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured Tagged With: GE Healthcare, SonoThera

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS